AGEN news

Latest 1 stories · newest Aug 6, 2026

AGEN

Agenus advances Phase 3 ROBBIN trial of BOT+BAL in MSS colon cancer

Agenus reported Q2 2026 results and announced an accelerated Phase 3 trial for neoadjuvant colon cancer. The trial is fully funded via a July 2026 private placement and addresses a multi-billion dollar annual market opportunity.

Offering Aug 6, 2026 sentiment +0.10 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same AGEN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/AGEN/newsSTART FREE